| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
αvβ3 integrin is overexpressed in endothelial cells and various tumor cells including pancreatic cancer. In this study, we developed RGD-modified liposomes for imaging and internal radionuclide therapy of pancreatic cancer. We successfully synthesized the RGD-modified liposomes with about 100 nm of particle size. The RGD-modified liposomes dose-dependently inhibited the binding of 125I-echistatin to PANC-1. The IC50 values were 5-67 μM as phospholipids. In contrast, RKG-modified liposome and unmodified liposome did not inhibit the binding. Biodistribution studies using the liposomes loaded with 111In indicated rapid clearance of the RGD-modified liposome from blood. Significant accumulation of radioactivity in spleen was found with increase in the amount of RGD modification (170.4-403.9% ID/g at 24 h). Unmodified liposome showed the highest tumor uptake (2.80% ID/g) at 24 h, whereas the RGD-modified liposomes showed the lower tumor uptake (1.47-2.25% ID/g).
|
